A LIM1TED number of reports have appeared in the literature over the last 20 years related to active immunization of patients with gliomas. 3"4"7"8"23 With one exception, 3 the data from these studies have not addressed the issue of therapeutic efficacy. Furthermore, none of these studies has attempted to document the immunological responses of the immunized patient in a consistent prospective manner. In this paper, we describe the results of several serological analyses conducted in 19 of 20 patients as part of a prospective Phase I pilot study in which selected patients with anaplastic gliomas were actively immunized with one or the other of two well characterized human glioma cell lines. One patient (Case 8) died only 2 months after beginning therapy and is not included in this report.
Specific details of this Phase I pilot study, including patient selection criteria, immunotherapeutic protocol, follow-up clinical tests, and evaluations of general immune competence, are described in the companion paper, Part 7 of this series. ~5 The specific serological studies reported here include determination of 1) percent reactive (anti-histocompatibility antigen (HLA)) antibody (PRA) and, in a limited number of cases, titration of anti-HLA serum antibody activity; and 2) the extent and specificity of binding of antibody to tumor cell surface antigens as detected by both protein A and antibody-mediated complement-dependent cytotoxicity directed against tumor cells.
Materials and Methods

Human Tumor Cells
Most of the in vitro assays were conducted using well established human tumor cell lines, Two human glioma lines, D-54MG and U-251MG, have been extensively described in the past, 1,2,5,25-27 and 2-T is an established human osteogenic sarcoma cell line 2~ that has been shown by absorption studies with nonhuman primate antisera 27 to share some antigenic determinants with human glioma lines. Two recently established lowpassage cultures of glioblastoma multiforme tumor cells (333T and 334T), together with a culture established from normal brain tissue of the former case (333NB), were used in a series of experiments which absorbed serum samples from one of the immunized patients. These cell lines are maintained in a tissue culture using Richter's zinc-option modification 2~ of Dulbecco's minimum essential medium (ZO-MEM) supplemented to 20% with endotoxin-free fetal bovine serum (FBS). All lines are carried in this antibiotic-free culture medium and have consistently shown negative results in routine tests for Mycoplasma. 6 
Separation and Storage of Serial Serum Samples"
For the antibody-binding studies, serum was obtained from patients just prior to their monthly immunization inoculations. Serum was also obtained monthly from 20 normal individuals for control studies. Blood was drawn into glass-stoppered tubes and allowed to clot at room temperature for 1 to 3 hours, then centrifuged at 2000 rpm for 20 minutes. The serum was then removed to a separate container for storage at -90~ until assayed.
Serum Studies
Human Lymphocyte Reactive (HLA) Antibody Assays'. Using a sensitive cytoxicity assay employing the addition of a heterologous anti-human immunoglobulin (AHG),12 serum samples from each patient obtained prior to immunization, and monthly thereafter, were tested undiluted and diluted 1:4 to monitor the development of antibodies that might be directed against HLA antigens expressed by the immunizing glioma cell lines. The test panel consisted of peripheral blood lymphocytes from 20 normal donors selected to represent 53 of the 59 recognized HLA-A, -B, -C specificities. Most antigens were expressed more than once within the cell panel. The PRA for each serum sample (diluted or undiluted) was determined by the number of cell panel members with lymphocytes that showed more than 20% cell death; for example, a widely reacting antiserum that killed at least 20% of the cells in half of the panel would be scored as a 50% PRA.
In a few instances, selected patient serum samples were titered by serial twofold dilution using lymphocytes from just those cell panel members against which the patient serum had reacted positively in previous assays. This permitted comparison of the titration end points determined by the antiglobulin technique with the degree of PRA.
Antibody-Binding Assay. A modification of the staphylococcal protein A (SPA) assay was used to detect binding of serum antibodies to tissue-cultured cell lines. Overnight incubation (at 37~ in 5% CO2) resulted in a submaximally confluent monolayer of target cells. The medium was dumped from each plate and 50 ul of each heat-inactivated (at 560C for 30 minutes) test serum sample (at 1:4, 1:16, and 1:32 dilutions) were added to each of three wells. The plates were incubated for 1 hour at 37~ the wells were then washed twice with Hank's balanced salt solution with 1% bovine serum albumin (HBSS-BSA), and 50 tA of iodine-125 (~25I)-SpA (105 cpm) was added to each well. After incubation for I hour at ambient temperature, each plate was washed twice with HBSS-BSA and allowed to drain. The contents of each well were solubilized in 200 ul of 2N sodium hydroxide, and 100 ul was sampled from each well for gamma scintillation counting of radioactivity. The change in antibody binding with immunization was determined for each patient's unabsorbed serum samples, using SpA data from the 1:4 dilutions of serial serum samples, and expressed as a ratio of the mean counts per minute (cpm) of each postimmunization serum sample to that of the preimmunization sample, assayed simultaneously. Serial serum samples (unabsorbed) from apparently healthy individuals without significant clinical histories were uniformly consistent in a lack of significant binding activity, with less than a 10% variation among them. For ease of comparison, the majority of the antibody assays were performed using as control serum a single lot from one healthy male donor. The mean cpm obtained in subsequent SpA assays performed with variously absorbed serum samples from the immunized patients were compared to the mean cpm of similarly absorbed serum samples from the normal control samples assayed simultaneously. For both types of comparisons (with unabsorbed and sequentially absorbed serum samples), the significance of the differences in binding was determined at the 99% confidence level utilizing Student's t-test.
Fetal bovine serum has been shown by others to become incorporated into tissue culture cells from the medium. 1~ Therefore, for each serum sample found on initial SpA testing to have an antibody activity to 0  0  21  58  65  55  60  99  90  85  NT  NT  NT  6  AI, A3, A11  0  0  0  25  65  45  60  50  50  50  NT  NT  NT  7  AI, B7, B8  32  16  40  50  30  95  85  85  NT  NT  NT  NT  NT  9  A1, A3, A11, B24, B28  0  0  50  65  55  55  55  50  55  70  80  85  80  I0  multiple, B8  0  60  90  70  80  80  80  90  95  NT  NT  NT the immunizing cell line, it seemed appropriate to determine the degree ofanti-FBS antibodies responsible for such binding. Using the cyanogen bromide method of March, et al., 18 FBS was covalently coupled to Sepharose 4B beads. Absorption studies were undertaken to ensure complete removal of all FBS activity. A 1-to 2-ml sample of patient serum was absorbed serially with 0.2 ml aliquots of packed FBS-Sepharose 4B beads. After each absorption, the beads were washed and assayed for presence of bound antibody, as detected by 125I-protein A. Absorption was judged complete when the amount of 125I-protein A bound to the beads used for absorption declined to, and remained at, background levels. Usually six serial absorptions completely removed all anti-FBS activity. This procedure permitted a comparison of a control (non-glioma) patient serum binding with the most reactive postimmunization serum binding prior to and after complete anti-FBS absorption.
Serum samples showing significant binding following complete absorption of anti-FBS antibodies were subjected to three absorption procedures against pooled human platelets ( 10 9 platelets/0.5 ml serum/absorption) to remove antibodies directed against HLA antigens. The samples were then re-assayed for evidence of significant antibody binding to cultured cell lines.
Those few serum samples that continued to bind in significant amounts after absorption with FBS and platelets were absorbed against an osteogenic sarcoma cell line (2-T). Previous studies had shown that all remaining non-glioma reactivity in antiserum from immunized nonhuman primates could be removed by this method, thereby leaving intact glioma-specific antibody reactivity. 27 Each serum sample was diluted 1:4 in FBS and absorbed once against packed 2-T cells, using five volumes of serum to one of cells. In these relatively few instances, the binding assay was repeated on cultured cell lines, using pre-absorbed, FBS-absorbed, FBS-and platelet-absorbed, and FBS-, platelet-, and 2-T-absorbed samples, to determine the amount, if any, of remaining anti-glioma antibody.
Humoral Cytotoxicity Tests. Antibody-mediated, complement-dependent serum cytotoxicity was measured using two radioisotopic assays. The carbon-14 (~4C)-nicotinamide release technique was performed essentially as described previouslyY Values less than 25 % were not considered to indicate significant specific release due to antibody-mediated cytolysis. Complement (young rabbit) background release (as opposed to spontaneous release in the presence of medium alone) was between 4% and 7 %, following complement absorption with agarose. Maximum release mediated by antibody (polyvalent primate anti-U-251MG serum) and complement was uniformly greater than 90%.
Results
Human Lymphocyte Reactive (HLA) Antibody Assays
The extent to which each patient developed anti-HLA antibodies in response to immunization with a glioma cell line was followed at monthly intervals by measuring the PRA to a panel of normal donor lymphocytes (Tables 1 and 2 ). The average PRA values for both groups of patients at each month are compared in Fig. 1 and do not differ greatly. Four patients (Cases 1, 1 1, 12, and 16) failed to develop a PRA greater than 10%. All other patients developed varying levels of PRA that usually increased during the first 3 to 4 months before reaching a plateau. Eight of the 10 patients immunized with the D-54MG cells and followed for more than 2 months developed a significant PRA level (> 10%), detectable as early as within the first 3 months in seven. Of the nine patients immunized with U-251MG cells, seven developed significant PRA, one of these only after 4 months of immunization. Of the four patients (Cases 3, 7, 14, and 19) whose sera indicated significant PRA prior to glioma immunization, two females (Cases 14 and 19) were multiparous and one female (Case 7) had received blood transfusions, which might explain this finding; one male (Case 3) had never received a whole-blood transfusion. Of the other 15 Before  l  2  3  4  5  6  7  8  9  10  11  12   12  0  0  0  0  0  0  0  0  0  0  0  0  NT  13  A2, A28  0  0  25  35  30  30  35  40  55  61  61  61  55  14  A2, A28  60  NT  95  99  90  90  NT  95  NT  99  99  99  NT  15  AI, A28, Bw51  0  0  0  0  90  90  90  80  95  90  95  50  61   16  0  0  0  0  0   NT  NT  NT  NT  NT  NT  NT  NT  17  A2, A28  0  0  0  30  20  35  NT  NT  NT  NT  NT  NT  NT  18  A2  0  0  0  0  0  0  0  0  0  0  11  30  23  19  Bw44  85  80  85  85  80  85  88  88  83  83  78  57  60  20  A2, A28  0  0  0  20  25  60  60  60  60  60  60  67 Table 2) .
Twenty-three of 371 serum samples showed prozone activity, which was low (6.2%) within the normal variation of lymphocytotoxicity testing, and disappeared at 1:4 dilution in all cases. There was no consistency in the observation of prozones a m o n g certain patients or certain samples. Titration end points of anti-HLA activity were determined from exemplary serum samples selected for high and low PRA levels at approximately 3 to 6 months following first immunization. A representative comparison between PRA and serum titer against two of the 20 to 30 panel cells used in determining overall P R A is given in Table 3 . Both cells expressed H L A antigens to which the patients had produced antibody. Cases 3 and 14 demonstrated high percent reactivity with H L A testing at these intervals; they also showed high serum reactivity with serial dilutions. Cases 6 and 15 showed both lower percent reactivities and lower serum titers at similar time intervals. binding to the immunizing cell line with time. Furthermore, it was noted that those patients inoculated with the D-54MG cell line developed a stronger overall antibody response than those inoculated with the U-251MG cell line. In a few cases, the binding activity tended to decline during the later course of their serial evaluations.
Antibody-Binding Assays
Serial results of total (unabsorbed, 1.4 dilution) serum antibody-binding activity against D-54MG glioma cells during immunization
In an effort to determine the degree of binding attributable to antibodies that were recognizing FBS antigens intercalated in the membranes of the injected glioma cells, real unabsorbed serum samples with the greatest antibody activity from each patient were absorbed exhaustively against FBS immobilized on Sepharose 4B, and tested once again for binding to the immunizing cell line as well as the osteogenic sarcoma, 2-T. This procedure usually diminished the binding antibody activity strikingly (up to 90%), and completely eliminated any significant binding by sera from seven of the eight responding patients (Table 6) .
Those sera with significant binding after depletion of antibody to FBS were further absorbed with pooled human platelets to remove antibodies directed against HLA antigens. This second absorption step completely eliminated significant serum antibody binding from an additional nine patients (Table 7) , leaving only two patients with persistent significant binding. Further absorption of serum samples from the two remaining patients against the 2-T osteogenic sarcoma cell line completely eliminated significant binding in one case. More importantly, this now identified a single patient whose absorbed serum contained antibody that bound to glioma target cells in significant amounts (Table 8) . The specificity and functional activity of this patient's sera were studied further as described below.
Serial results of total (unabsorbed, 1.'4 dilution) serum antibody-binding activity against U-251MG glioma cells during immunization
Further Serological Studies in Case 20
Because of the significant antibody-binding activity to the U-251MG cell line in the 12-month serum sample of Case 20 after absorption, additional serum samples taken at 14, 15, and 16 months were studied (Table  9 ). Although each of those samples contained postabsorption anti-U-251MG antibody binding, the magnitude of binding was progressively less in the samples beyond 12 months, during which time the patient continued to be actively immunized.
Since the 12-month sample contained the highest specific binding to U-251 MG, additional binding assays were carried out, both before and after absorption, against low-passage cultures derived from two glioblastoma multiforme neoplasms (333T and 334T) as well as a low-passage culture (333NB) established from normal brain (perhaps infiltrated with glioma) of the former case (Table 10 ). The post-absorbed sera bound significantly to U-251MG cells and to a lesser, but still significant, extent to the 334T cells. There was no significant activity against the D-54MG, 333T, or the 333NB cell cultures after extensive absorptions. This serum sample, before and after absorption, was then titrated against the U-251MG cell line using the ~4C-nicotinamide humoral cytotoxicity assay (Fig. 2) . By this method, antibody-mediated, complement-dependent killing of U-251 MG glioma cells decreased in extent with each absorption step performed, yet remained at a significant level after reactivity to the non-glioma antigens was depleted. This stepwise reduction in cytotoxicity mirrored the progressive decrease in antibodybinding activity that occurred with each absorption step (Table 10) . A sample of unabsorbed cerebrospinal fluid, drawn by lumbar puncture at 17 months and diluted 1"4, 1:16, and 1:32, was found not to have any antibodybinding activity against U-251MG, D-54MG, or 2-T (data not shown).
Discussion
These results suggest that immunization of humans with anaplastic glioma cells by this protocol tends to evoke an antibody response that is primarily directed against xenogeneic antigens (FBS) irreversibly introduced into the tissue-cultured glioma cells together with a significant amount of antibody directed against HLA antigens. Beyond that, further absorption of reactive sera against another human cancer line (2-T) removed all significant binding antibody except in one patient (Case 20) who appeared to have a remaining binding and cytotoxic antibody with U-251MG specificity.
The magnitude of the antibody response evoked in the majority of these patients to FBS and HLA antigens was somewhat surprising, in view of the meager antibody responses seen previously in patients with gliomas who were immunized with tetanus and influenza antigens, ~6 or with the neo-antigen, KLH (keyhole limpet hemocyanin) (unpublished data, 1975 ). There were, however, considerable differences in the immunization protocols performed in this series of patients, compared with the earlier serological studies. First, the 19 patients evaluated from this present series were selected on the basis of an indication of immune competence. In gen- eral, most glioma patients have depressed immune function? 7 Second, each patient in this series was presented with strong xenogeneic (FBS) antigens, intercalated into the tumor cell membranes from the tissue culture medium, together with foreign HLA antigens, since no attempt was made to match each patient with the HLA profile of the D-54MG or U-251MG cell line. Finally, immunization was initiated using bacillus Calmette-Gu6rin (BCG) cell walls as an adjuvant which we have not used in previous clinical studies. In all of the patients who did demonstrate a serological response, the quantity of antibody tended to increase as the early immunizations progressed. Once antibodies to FBS and HLA antigens were depleted (by appropriate absorptions) from each patient's sera sample that had the greatest initial binding activity, only two patients' sera contained significant antibody-binding activity to the cell line used for immunization (D-54MG or U-251 MG). Additional absorption with the 2-T osteogenic sarcoma cell line, previously used to render monkey antisera specific for glioma cell surface antigens, removed all significant antibody binding to D-54MG in one patient's serum (Case 1), but left significant antibody that bound to U-251MG in the other (Case 20). In this one instance, a specific or distinctive anti-glioma antibody may have been present.
Study of subsequent serum samples in this patient at 14, 15, and 16 months revealed sequentially decreasing quantities of antibody but persistent post-absorption significant binding to the U-251MG cell line at all times. The relative specificity of the 12-month serum sample was evaluated for the unabsorbed and the variously absorbed samples (Table 10) , comparing binding to the immunizing cell line (U-251MG) with that to D-54MG, 2-T, and three other human brain-tumor tissue cultures (334T, 333T, and 333NB). Complete absorptions eliminated all binding except to U-251MG (the long-term immunizing glioblastoma cell line) and 334T (a recently cultured glioblastoma cell line).
In an effort to compare a primary function of antibody (that is, binding to antigens expressed on glioma cell surfaces) to a secondary antibody function (complement-dependent cytotoxicity against glioma cells), the extensively absorbed, 12-month serum sample from Case 20 was tested in vitro for ability to mediate complement-dependent cell killing. The ~4C-nicotinamide assay revealed that the unabsorbed serum was cytotoxic, with progressive reduction in the degree of cytotoxicity with more complete absorptions (Fig. 2 ), yet remaining significantly cytotoxic after absorption was complete.
The longer survival noted overall for the patients inoculated with U-251 MG compared to those receiving D-54MG has been an observation coincidental with less severe local dermal reactions at the inoculation sites, js and with tendencies to produce more intense binding antibody as determined by the SpA assay among the U-251 MG-inoculated patients. These coincidental findings will require further investigation in a larger series of immunized patients.
Yet to be evaluated is the relative importance of the nature of the immunogen: homologous versus autologous ceils, fresh versus tissue-cultured and/or freezethawed cells, irradiated versus non-irradiated cells, and presence or absence of adjuvant. Any of these considerations in addition to other strategic issues, such as the interaction of immunization with radiotherapy and chemotherapy, probably influence immune responses of the patient and, perhaps, therapeutic response. It must be borne in mind that these 19 patients were specifically screened to ensure that they possessed some indication of immune competence. Nevertheless, the unique serological results with one patient (Case 20) raise several other questions related to the nature of the antibody response and its relationship, if any, to survival. It would be most important to evaluate this and similar antibodies exhaustively, perhaps by human Bcell hybridization and monoclonal anti-glioma antibody isolation, for diagnostic and therapeutic study. 24 Such antibodies might be useful as diagnostic probes because of their localization in glioma tissue, and might serve therapeutically as cytotoxic molecules or as vectors to glioma tissue, delivering boron for use in neutron capture radiotherapy, radioisotopic radiotherapy, or covalently bound chemotherapeutic poisons.
